Teva Targets $6–7B Innovative Medicines Revenue by 2030
Tel Aviv, Israel, and Parsippany, New Jersey, U.S., November 11, 2026 Teva Pharmaceutical Industries Ltd. has unveiled its next...
innovative medicines
Advertisement
Teva Reports 33% Growth Across Three Innovative Brands
Tel Aviv, Israel, November 3, 2026 Teva Pharmaceutical Industries Ltd. has reported strong growth across its three key innovative...
InnoCare and Lilly Sign $3.35B Drug Discovery Deal
Beijing, China, September 24, 2026 InnoCare Pharma has entered into a strategic research collaboration and license agreement with Eli...
Insilico Rentosertib Shows Potential for Biological Age Reversal
New York, USA, September 7, 2026 Insilico Medicine’s AI-driven investigational drug rentosertib has demonstrated potential to reduce measures of...
Teva Reaches Investment Grade With S&P BBB- Upgrade
Tel Aviv, Israel, September 4, 2026 Teva Pharmaceutical Industries Ltd. has received an upgrade to BBB- from BB+ for...
Advertisements
ArkBio Advances AK0406 with China IND Approval
Shanghai, China, August 12, 2026 Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced that China’s National Medical Products Administration (NMPA)...
Teva Earns Investment-Grade Rating as Growth Strategy Advances
TEL AVIV, Israel, August 11, 2026 Teva Pharmaceutical Industries Ltd. announced that Moody’s Ratings has upgraded the company’s corporate...
Akeso Wins NMPA Approval for Gumokimab in Plaque Psoriasis
HONG KONG, June 11, 2026 Akeso, Inc. announced that China’s National Medical Products Administration (NMPA) has approved gumokimab (AK111,...
Fosun Pharma Signs Global Option Deal for AriBio’s AR1001
SHANGHAI and SEONGNAM-SI, South Korea, May 13, 2026 Fosun Pharma and AriBio announced the signing of an exclusive global...
Advertisement
